Skip to content
5WPR
Get in touch
Ragan PR Daily Awards5W is a 2026 PR Agency of the Year FinalistRagan's PR Daily Awards · Read the announcement →

RESEARCH · Published May 23, 2026 · Updated November 8, 2026

Obesity Drugs Index 2.0: Eli Lilly Leads in AI Answers

Eli Lilly: 284/288 (98.6%; 95% interval 96.5–99.5%). Novo Nordisk: 242/288 (84.0%; 95% interval 79.4–87.8%).

288

AI answers analyzed across ChatGPT, Claude, Gemini and Perplexity

98.6%

of answers named Eli Lilly, the most-named (284 of 288)

24

tracked companies named at least once (of 24)

95%

of Google searches showed an AI Overview (57 of 60)

Version 2. This version replaces the first version of this study, first published May 23, 2026. It uses measured counts, so the two versions are not comparable. Version 2 asks 24 questions three times each on ChatGPT, Claude, Gemini and Perplexity (288 answers) and adds Google AI Overviews. Every rate comes with its count and a 95% interval.

What the data shows

01

Eli Lilly

Eli Lilly leads this measured set. Eli Lilly: 284/288 (98.6%; 95% interval 96.5–99.5%). Novo Nordisk: 242/288 (84.0%; 95% interval 79.4–87.8%).
02

135/288 (46.9%)

Eli Lilly was the first company named in 135 of 288 answers, more than any other tracked company. Its average first position was 1.9.
03

53/288 (18.4%)

Eli Lilly's own domains were cited in 53 of 288 grounded answers, more than any other tracked company. WeightWatchers followed at 30 of 288. 7 of 24 tracked companies had 0 of 288.
04

57/60 (95%)

Google AI Overviews appeared on 57 of 60 searches (CI 86.3–98.3%). On the other 3, no overview was shown.
05

56/57 (98.2%)

Eli Lilly was the company named most often in AI Overviews, at 56 of 57, followed by Novo Nordisk at 42 of 57 (73.7%). In the four-engine set, Eli Lilly was named in 284 of 288 answers (98.6%).
06

74/288 (25.7%)

drugs.com was cited in 74 of 288 grounded four-engine answers, with 99 of 2,425 citations (4.1%). goodrx.com came second with 64 citations in 55 answers (19.1%).

Appearance rate across 288 four-engine answers. The bar is the 95% confidence interval; overlapping bars cannot be told apart at this sample size.

Which brands AI engines name

Eli Lilly
98.6%
Novo Nordisk
84.0%
AstraZeneca
30.2%
Pfizer
24.7%
Roche
22.9%
Amgen
20.1%
Boehringer Ingelheim
18.1%
Merck
17.0%
Johnson & Johnson
15.6%
Sanofi
15.3%
Ro
12.5%
AbbVie
12.2%
Viking Therapeutics
12.2%
WeightWatchers
10.8%
Structure Therapeutics
10.1%
#NameNamed inAppearance rate95% interval
1Eli Lilly284/28898.6%96.5–99.5%
2Novo Nordisk242/28884.0%79.4–87.8%
3AstraZeneca87/28830.2%25.2–35.7%
4Pfizer71/28824.7%20.0–29.9%
5Roche66/28822.9%18.4–28.1%
6Amgen58/28820.1%15.9–25.1%
7Boehringer Ingelheim52/28818.1%14.0–22.9%
8Merck49/28817.0%13.1–21.8%
9Johnson & Johnson45/28815.6%11.9–20.3%
10Sanofi44/28815.3%11.6–19.9%
11Ro36/28812.5%9.2–16.8%
12AbbVie35/28812.2%8.9–16.4%
13Viking Therapeutics35/28812.2%8.9–16.4%
14WeightWatchers31/28810.8%7.7–14.9%
15Structure Therapeutics29/28810.1%7.1–14.1%

The full list

Own-domain citation is the share of 288 grounded answers that cited the tracked name's own domains (subdomains included). Citation share is of all 2,425 citations.

#BrandNamed inAppearance rate95% intervalFirst mentionOwn-domain citationCitation share
1Eli Lilly284/28898.6%96.5–99.5%1.918.4% (53/288)2.6%
2Novo Nordisk242/28884%79.4–87.8%2.18% (23/288)1.1%
3AstraZeneca87/28830.2%25.2–35.7%4.61% (3/288)0.1%
4Pfizer71/28824.7%20–29.9%4.62.1% (6/288)0.2%
5Roche66/28822.9%18.4–28.1%4.30.3% (1/288)0%
6Amgen58/28820.1%15.9–25.1%5.10.3% (1/288)0%
7Boehringer Ingelheim52/28818.1%14–22.9%4.41.7% (5/288)0.2%
8Merck49/28817%13.1–21.8%4.90% (0/288)0%
9Johnson & Johnson45/28815.6%11.9–20.3%3.40% (0/288)0%
10Sanofi44/28815.3%11.6–19.9%4.80% (0/288)0%
11Ro36/28812.5%9.2–16.8%2.96.6% (19/288)0.8%
12AbbVie35/28812.2%8.9–16.4%4.90% (0/288)0%
13Viking Therapeutics35/28812.2%8.9–16.4%5.81.4% (4/288)0.2%
14WeightWatchers31/28810.8%7.7–14.9%3.210.4% (30/288)1.3%
15Structure Therapeutics29/28810.1%7.1–14.1%60.7% (2/288)0.1%
16Biogen28/2889.7%6.8–13.7%2.62.1% (6/288)0.2%
17Eisai24/2888.3%5.7–12.1%1.81.4% (4/288)0.2%
18Zealand Pharma24/2888.3%5.7–12.1%6.50% (0/288)0%
19Hims & Hers21/2887.3%4.8–10.9%5.12.8% (8/288)0.4%
20Noom21/2887.3%4.8–10.9%4.46.3% (18/288)0.7%
21Found15/2885.2%3.2–8.4%3.93.8% (11/288)0.5%
22Mochi Health14/2884.9%2.9–8%5.90% (0/288)0%
23Calibrate12/2884.2%2.4–7.1%4.72.8% (8/288)0.3%
24Henry Meds3/2881%0.4–3%100% (0/288)0%

Second table: drug brands

Drug-brand names in 288 four-engine answers. Each drug mention is also credited once per answer to its maker in the main company ranking.

#Drug brandNamed answersRate95% intervalNamed first
1Zepbound166/28857.6%51.9–63.2%50
2Wegovy163/28856.6%50.8–62.2%68
3Mounjaro125/28843.4%37.8–49.2%21
4Ozempic118/28841.0%35.4–46.7%43
5Rybelsus77/28826.7%22.0–32.1%3
6Foundayo75/28826.0%21.3–31.4%18
7Trulicity53/28818.4%14.4–23.3%2
8Saxenda50/28817.4%13.4–22.2%1
9CagriSema38/28813.2%9.8–17.6%12
10LillyDirect30/28810.4%7.4–14.5%2
11Januvia26/2889.0%6.2–12.9%4
12Farxiga24/2888.3%5.7–12.1%3
13Jardiance24/2888.3%5.7–12.1%1
14Leqembi24/2888.3%5.7–12.1%16
15Kisunla22/2887.6%5.1–11.3%8
16NovoCare Pharmacy16/2885.6%3.4–8.8%1

The top eight, side by side

#NameAppearance rateAnswers and intervalOther measures
1Eli Lilly98.6%284/288 answers · 95% CI 96.5–99.5%first-mention position: 1.9; owned-domain citation (53/288): 18.4%; citation share: 2.6%
2Novo Nordisk84.0%242/288 answers · 95% CI 79.4–87.8%first-mention position: 2.1; owned-domain citation (23/288): 8%; citation share: 1.1%
3AstraZeneca30.2%87/288 answers · 95% CI 25.2–35.7%first-mention position: 4.6; owned-domain citation (3/288): 1%; citation share: 0.1%
4Pfizer24.7%71/288 answers · 95% CI 20–29.9%first-mention position: 4.6; owned-domain citation (6/288): 2.1%; citation share: 0.2%
5Roche22.9%66/288 answers · 95% CI 18.4–28.1%first-mention position: 4.3; owned-domain citation (1/288): 0.3%; citation share: 0%
6Amgen20.1%58/288 answers · 95% CI 15.9–25.1%first-mention position: 5.1; owned-domain citation (1/288): 0.3%; citation share: 0%
7Boehringer Ingelheim18.1%52/288 answers · 95% CI 14–22.9%first-mention position: 4.4; owned-domain citation (5/288): 1.7%; citation share: 0.2%
8Merck17.0%49/288 answers · 95% CI 13.1–21.8%first-mention position: 4.9; owned-domain citation (0/288): 0%; citation share: 0%

The four engines named the leading names at similar rates.

ChatGPT

72 asked · 72 returned · 72 grounded

Same questions, different answers

Eli Lilly
98.6%
Novo Nordisk
81.9%
AstraZeneca
29.2%
Pfizer
26.4%
Sanofi
20.8%
Amgen
19.4%

Claude

72 asked · 72 returned · 72 grounded

Eli Lilly
100.0%
Novo Nordisk
87.5%
AstraZeneca
27.8%
Pfizer
20.8%
Roche
20.8%
Amgen
19.4%

Gemini

72 asked · 72 returned · 72 grounded

Eli Lilly
95.8%
Novo Nordisk
84.7%
AstraZeneca
36.1%
Pfizer
30.6%
Roche
25.0%
Amgen
22.2%

Perplexity

72 asked · 72 returned · 72 grounded

Eli Lilly
100.0%
Novo Nordisk
81.9%
Roche
29.2%
AstraZeneca
27.8%
Pfizer
20.8%
Boehringer Ingelheim
20.8%

Google AI Overviews were captured through 60 U.S. desktop searches and scored only where an overview appeared, so five-engine figures use 288 + 57 = 345 answers.

The fifth engine

95%

Trigger rate: 57 of 60 searches

Google AI Overviews appeared on 57 of 60 searches (95%, CI 86.3–98.3%). The other 3 searches showed no overview. Within the 57 overviews, Eli Lilly was named in 56 (98.2%), Novo Nordisk was named in 42 (73.7%), AstraZeneca was named in 14 (24.6%), Roche was named in 14 (24.6%). jamanetwork.com was the most-cited source, with 35 citations and an appearance in 18 of 57 overviews.

Five-engine rankNameFive-engine rateFour-engine rank
1Eli Lilly98.6%1
2Novo Nordisk82.3%2
3AstraZeneca29.3%3
4Pfizer24.1%4
5Roche23.2%5
6Amgen20.9%6
7Boehringer Ingelheim18.0%7
8Merck16.8%8
9Johnson & Johnson14.2%9
10Sanofi13.6%10

Who each question surfaces first

Six questions from the set. Each tile uses that question's own four-engine answers as the denominator.

QuestionLeaderNextAI Overview
Q01 · 12 answersEli Lilly 100.0%Novo Nordisk 100.0%; Roche 25.0%AI Overview shown on 2 of 3 searches
Q02 · 12 answersEli Lilly 100.0%Novo Nordisk 100.0%AI Overview shown on 3 of 3 searches
Q03 · 12 answersEli Lilly 100.0%Novo Nordisk 100.0%AI Overview shown on 3 of 3 searches
Q04 · 12 answersNovo Nordisk 100.0%Eli Lilly 100.0%; AstraZeneca 75.0%AI Overview shown on 3 of 3 searches
Q05 · 12 answersEli Lilly 100.0%Novo Nordisk 100.0%; Pfizer 91.7%AI Overview shown on 3 of 3 searches
Q06 · 12 answersViking Therapeutics 100.0%Novo Nordisk 91.7%; Structure Therapeutics 83.3%AI Overview shown on 3 of 3 searches

The four engines produced 2,425 citations in total. drugs.com was cited most often, with 99 citations (4.1%) across 74 answers. Next came goodrx.com (64), pmc.ncbi.nlm.nih.gov (57), forbes.com (45), fda.gov (37), healthline.com (37).

Four AI engines · share of 288 grounded answers

Most-cited domains

drugs.com
25.7%
goodrx.com
19.1%
pmc.ncbi.nlm.nih.gov
14.6%
forbes.com
11.5%
healthline.com
10.8%
fda.gov
10.1%
weightwatchers.com
10.1%
ozmosi.com
9.4%
mayoclinic.org
8.3%
delveinsight.com
8.3%

Google AI Overviews · share of 57 overviews

jamanetwork.com
31.6%
youtube.com
31.6%
goodrx.com
12.3%
facebook.com
10.5%
mayoclinic.org
10.5%
weightwatchers.com
8.8%
diabetesjournals.org
7.0%
en.wikipedia.org
7.0%
diabetes.org
7.0%
obesitymedicine.org
7.0%

Citation share by source type

Share of all citations by the type of site cited.

Source typeFour AI engines (of 2,425 citations)Google AI Overviews (of 268 citations)
Other / unclassified891 (36.7%)76 (28.4%)
Company / brand sites324 (13.4%)23 (8.6%)
General news / business press275 (11.3%)8 (3%)
Official / government252 (10.4%)15 (5.6%)
Health publishers247 (10.2%)22 (8.2%)
Community / social127 (5.2%)48 (17.9%)
Research / data providers126 (5.2%)49 (18.3%)
Institutions / trade bodies69 (2.8%)17 (6.3%)
Trade / specialist press37 (1.5%)3 (1.1%)
Review / comparison publishers32 (1.3%)0 (0%)
Reference31 (1.3%)5 (1.9%)
Directories / rankings14 (0.6%)2 (0.7%)

How can brands improve their AI visibility?

These steps follow from the measured results above. They describe what the engines cited in this study and are not a guarantee of results.

StepWhat this study measured
Put your facts on your own domain.Eli Lilly's own domains were cited in 18.4% of grounded answers, WeightWatchers' in 10.4% and Novo Nordisk's in 8.0%.
Keep your facts accurate on the sites engines cite.The most-cited sites other than the tracked names' own were drugs.com (in 25.7% of grounded answers), goodrx.com (19.1%), pmc.ncbi.nlm.nih.gov (14.6%), forbes.com (11.5%) and healthline.com (10.8%). General news and business press supplied 11.3% of citations and official and government 10.4%.
Check each engine separately.Gemini named Viking Therapeutics in 22.2% of answers against 5.6% on ChatGPT. ChatGPT named Sanofi in 20.8% of answers against 8.3% on Perplexity.
Watch names outside the tracked list.Wegovy (52 answers), Zepbound (51 answers), Mounjaro (50 answers), Ozempic (50 answers), Rybelsus (35 answers) were named often but were not tracked.
Re-run the same questions every month.Compare counts and intervals, not ranks. The 24 questions are in the appendix.

What AI answers

Which companies lead these AI answers?

Eli Lilly leads this measured set. Eli Lilly: 284/288 (98.6%; 95% interval 96.5–99.5%). Novo Nordisk: 242/288 (84.0%; 95% interval 79.4–87.8%).

Which company is named first most often?

Eli Lilly was the first company named in 135 of 288 answers, with an average first position of 1.9.

How often do Google AI Overviews appear for these questions?

An overview appeared on 57 of 60 searches (95%, CI 86.3–98.3%). Within those 57 overviews, Eli Lilly was named most often, in 56 (98.2%).

Which sources do the engines cite?

Across 2,425 four-engine citations, drugs.com was cited most (99 citations, in 74 of 288 grounded answers), followed by goodrx.com (64 citations).

Do the four engines agree?

Largely. No tracked name differed by more than 12 points between engines.

How this study was measured

24 questions × 3 runs each × 4 AI engines = 288 answers + 60 Google searches · 57 AI Overviews

24 questions asked three times on each of ChatGPT, Claude, Gemini and Perplexity, measured November 3, 2026. United States, English; Google retrieval uses desktop results. Models: gpt-5-mini, claude-sonnet-5-5, gemini-3.6-flash only, sonar-pro. Google AI Overviews come from DataForSEO, not inferred chat answers. Appearance counts returned text, including ungrounded answers; citation rates use grounded answers. Longer overlapping names suppress shorter ones; First mention is the earliest eligible name order. Own-domain rates include declared domains and subdomains; shared parent scopes may count for multiple names and cannot be summed as unique citations.

EngineModel IDs calledAskedReturnedGrounded
ChatGPTgpt-5-mini727272
Claudeclaude-sonnet-5-5727272
Geminigemini-3.6-flash727272
Perplexitysonar-pro727272
Google AI OverviewsDataForSEO Google SERP (live, advanced)6057 shown57

Own-domain citations count a domain plus all its subdomains, with the same rule in every table.

Definitions

  • Appearance rate: answers naming the tracked name ÷ answers returned, with Wilson 95% intervals.
  • First mention: average order in which the tracked name first appears (1 = first).
  • Own-domain citation: grounded answers citing the tracked name's domains ÷ grounded answers.
  • Citation share: citations to the tracked name's domains ÷ all citations.

Limits

  • Only 24 tracked companies are ranked; results are not an exhaustive market ranking.
  • Only the tracked companies were scored. Untracked names that appeared often were not scored, including Wegovy (52 answers), Zepbound (51 answers), Mounjaro (50 answers), Ozempic (50 answers), Rybelsus (35 answers).
  • 348 of 360 planned results were returned. 12 AI Overview lookups were excluded after at most three total attempts.
  • 60 successful Google searches: 57 overviews shown; 3 without an overview. Failures are excluded, not scored as zero.
  • All returned chat answers had search sources.
  • Questions 2, 3 and 10 name Mounjaro, Ozempic, Zepbound and Wegovy, so each of those counts includes up to 12 answers to a question that names it.
  • Removing 3 Core questions naming tracked subjects leaves 252 eligible answers. The top two are Eli Lilly (248/252) and Novo Nordisk (218/252); their order does not change.
  • Unverified own domains are not available, never zero or guessed. Source types use Company / brand sites only for verified official organisations; other unresolved sites are Other / unclassified.
  • Wilson 95% intervals are descriptive; overlapping leading intervals do not establish a sole leader. Measurements do not endorse medical, legal, financial or product claims.
  • Covers the companies, branded drugs and telehealth providers named in obesity and type 2 diabetes questions, US market. Drug names are tracked in their own table and also credited to their maker. Status: Lilly's oral GLP-1 orforglipron was approved by the FDA as Foundayo on April 1, 2026. Novo Nordisk's CEO is Maziar Mike Doustdar, and its Wegovy pill launched before Foundayo. This report counts names in AI answers only. It makes no safety, efficacy or prescribing claim, and being named is not an endorsement. Questions are informational, not requests for medical advice. Main ranking: companies (drug makers and telehealth providers), with each drug-brand mention credited to its maker; the title and summary follow the Wilson rule on this company view. Drug brands are shown as a second table.
  • Google Shopping links and unresolved google.com/goto redirect links are not counted as cited sources; original URLs remain in the evidence.
  • Answers were collected through each engine's API using the model IDs listed in the methodology. The consumer ChatGPT, Claude, Gemini and Perplexity apps can answer differently.

The 24 questions

Questions marked "Core question" are the original study questions, asked word for word. The others are added neutral questions.

#QuestionGroupSource
01What are the most effective prescription weight-loss medications?Obesity Drugs Index 2.0Core question
02Mounjaro vs Ozempic: what is the difference?Obesity Drugs Index 2.0Core question
03Zepbound vs Wegovy: which works better for weight loss?Obesity Drugs Index 2.0Core question
04Which companies make GLP-1 drugs?Obesity Drugs Index 2.0Core question
05Which pharmaceutical companies lead in obesity treatment?Obesity Drugs Index 2.0Core question
06What oral weight-loss drugs are in development?Obesity Drugs Index 2.0Core question
07Where can I get GLP-1 medication online?Obesity Drugs Index 2.0Core question
08What are the leading pharmaceutical companies in the US?Obesity Drugs Index 2.0Core question
09Which companies are developing Alzheimer's treatments?Obesity Drugs Index 2.0Core question
10How much does Zepbound cost without insurance?Obesity Drugs Index 2.0Core question
11What are the newest FDA-approved weight-loss drugs?Obesity Drugs Index 2.0Added question
12What medications are used to treat type 2 diabetes?Obesity Drugs Index 2.0Added question
13What are the most commonly prescribed GLP-1 drugs for type 2 diabetes?Obesity Drugs Index 2.0Added question
14What are the newer types of diabetes medication besides metformin?Obesity Drugs Index 2.0Added question
15Are there weight-loss pills that work like GLP-1 injections?Obesity Drugs Index 2.0Added question
16Which drug companies have the strongest obesity drug pipelines?Obesity Drugs Index 2.0Added question
17What next-generation obesity drugs are in late-stage trials?Obesity Drugs Index 2.0Added question
18What are the best telehealth programs for medical weight loss?Obesity Drugs Index 2.0Added question
19How do online weight-loss programs prescribe GLP-1 medications?Obesity Drugs Index 2.0Added question
20What Alzheimer's drugs have been approved recently?Obesity Drugs Index 2.0Added question
21Which pharmaceutical companies have the biggest market value?Obesity Drugs Index 2.0Added question
22How much do GLP-1 medications cost per month in the US?Obesity Drugs Index 2.0Added question
23Which companies make insulin in the US?Obesity Drugs Index 2.0Added question
24What are the main differences between semaglutide and tirzepatide?Obesity Drugs Index 2.0Added question

About 5W

5W is an independent PR, creative and GEO agency founded in 2003, and we get you in the chatbox. All of our work is done in house, including media relations, site building and content. Learn more about our GEO practice or write to info@5wpr.com.

Full report

Read the PDF

Download PDF

Get in touch

Let's build your next chapter.

Tell us what you're working on. A senior strategist will respond within one business day.

Email
info@5wpr.com
Phone
212.999.5585
Offices
Miami · HQ100 SE 2nd Street, Floor 38
Miami, FL 33131
Tampa110 South 12th Street
Tampa, FL 33602
New York469 7th Avenue, Floor 8
New York, NY 10018